Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04629703 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT04629703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04629703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 25, 2021
Completion date
September 5, 2022
Enrollment
280 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, pneumonia, pneumonia, viral, sars (severe acute respiratory syndrome), sars pneumonia, sars-associated coronavirus as cause of disease classified elsewhere